- Investors are seeking greater upside potential in AI stocks. Inflation and utilization worries are impacting medtech valuations, which could benefit from tariffs.
- Trump-era tariffs are benefiting certain AI stocks, exemplified by Liquidia Corp. and its product Yutrepia, which treats pulmonary hypertension and interstitial lung disease.
The FDA approved YUTREPIA, a product from Liquidia Corporation, marking a key milestone.
4 reports, 3 independent
Updated Aug 18
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved YUTREPIA, a product from Liquidia Corporation, marking a key milestone.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- An unnamed company secured regulatory approval in July 2025, leading to a $2.5 million milestone reported today.
- FDA accepted Milestone's response to the Complete Response Letter (CRL).
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Intellia Therapeutics is seeking FDA approval for its drug Lonvo-Z.
- FDA approved Pasatru for FOP treatment.
Coverage
Newest first; wire copies grouped- Simply Wall St.3 Growth Companies Insiders Are Betting On As the Dow Jones Industrial Average reaches new heights while the S&P 500 and Nasdaq experience slight declines, investors are closely monitoring market mov
- Insider MonkeyLiquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge We recently published 10 Stocks on Euphoria. Are You Holding Any? Liquidia Corp. (NASDAQ:LQDA) is one of the best-performing stocks on Tu
- GlobeNewswireLiquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after appr
- Simply Wall St.3 Growth Companies With Insider Ownership Up To 25% As the U.S. stock market experiences fluctuations with indices like the S&P 500 retreating from record highs, investor optimism remains buoyed by s